medigraphic.com

2014, Number 4

<< Back Next >>

Rev Hosp Jua Mex 2014; 81 (4)

Inflammatory elements in patients with diabetes mellitus have higher levels than in non-diabetic patients. Some of these elements are present in ocular structures, where they participate actively in the pathogenesis of diabetic retinopathy and macular ede

Ávila-Alcaraz Y, Lima-GómezV

Language: Spanish
References: 34
Page: 226-230
PDF size: 121.08 Kb.


ABSTRACT

Inflammatory elements in patients with diabetes mellitus have higher levels than in non-diabetic patients. Some of these elements are present in ocular structures, where they participate actively in the pathogenesis of diabetic retinopathy and macular edema. Topical anti-inflammatory therapy is currently under evaluation as an adjunct therapy, for improving visual function in patients with vision threatening diabetic retinopathy.


REFERENCES

  1. Wautier JL, Guillausseau PJ. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab 2001; 27: 535-2.

  2. Sell DR, Monnier VM. Structure elucidation of a senescence cross-link from extracellular matrix. J Biol Chem 1989; 264: 21597-602.

  3. Schleicher ED, Wagner E, Nerlich AG. Increased accumulation of the glycoxidation product in human tissues in diabetes and aging. J Clin Invest 1997; 99: 457-8.

  4. Frye EB, Degenharkt, Thorpe SR, Baynes JW. Role of the Maillard reaction in aging of tissue proteins. J Biol Chem 1998; 273: 18714-9.

  5. Rumble JR, Coooper RE, Soulis E, et al. Vascular hyperthophy in experimental diabetes. Role of advanced glycation end products. J Clin Invest 1997; 99: 1016-27.

  6. Wautier JL, Wautier MP, Schmidt AM, et al. Advanced glycation end products (AGES) on the surface of diabetic red cells bind to the vassal wall via specific receptor inducing oxidant stress in the vasculature: a link between surfaceassociated AGES and diabetic complications. Proc Natl Acad Sci 1994; 91: 7742-6.

  7. Shiba T, Inoguchi T, Sportsman JR, Heath WF, Bursell S, King GL. Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am J Physiol 1993; 265: 783-93.

  8. Sharp PS. Growth factors in the pathogenesis of diabetic retinopathy. Diabetes Review 1995; 3: 164-76.

  9. Canataroglu H, Varinli I, Ozcan AA, Canataroglu A, Doran F, Vrinli S. Interleukin 8IL9-6, interleukin 8IL9-8 levels and cellular composition of the vitreous humor in proliferative diabetic retinopathy, proliferative vitreoretinopathy, and traumatic proliferative vitreoretinopathy. Ocul Inmunol Inflamm 2005; 13: 375-81.

  10. Murugeswari P, Shukla D, Rajendran A, Kim R, Namperumalsamy P, Muthukkaruppan V. Proinflammatory cytokines and angiogenic and anti-angiogenic factors in vitreous of patients with proliferative diabetic retinopathy and eales’ disease. Retina 2008; 28: 817-24.

  11. Petrovic MG, Osredkar J, Saraga-Babic M, Petrovic D. K469E polymorphism of the intracellular adhesion molecule 1 gene is associated with proliferative diabetic retinopathy in Caucasians with type 2 diabetes. Clin Experiment Ophthalmol 2008; 36: 468-72.

  12. Adamiec-Mroczek J, Oficjalska-Mlynczak J. Assessment of selected adhesion molecule and proinflammatory cytokine levels in the vitreous body of patients with type 2 diabetes role of the inflammatory-inmune process in the pathogenesis of proliferative diabetic retinopathy. Graefes rch Clin Exp Ophthalmol 2008; 246: 1665-70.

  13. Douglas Y, Bhatwadekar AD, Shaw LC, Carnegie D, Caballero S, Li Q, et al. Bone-marrow-CNS connections: implications in the pathogenesis of diabetic retinopathy. Prog Retin Eye Res 2012; 31: 481-94.

  14. Gerl VB, Bohl J, Pitz S, Stoffelns B, Pfeiffer N, Bhakdi S. Extensive deposits of complement C3d and C5b-9 in the choriocapillaris of eyes of patients with diabetic retinopathy. Invest Ophthalmol Vis Sci 2002; 43: 1104-8.

  15. Kowluru RA, Zhong Q, Kanwar M. Metabolic memory and diabetic retinopathy: role of inflammatory mediators in retinal pericytes. Exp Eye Res 2010; 90: 617-23.

  16. Zong H, Ward M, Madden A, Yong PH, Limb GA, Curtis TM, Stitt AW. Hyperglycaemia-induced pro-inflammatory responses by retinal Muller glia are regulated by the receptor for advanced glycation end-products (RAGE). Diabetologia 2010; 53: 2656-66.

  17. Ibrahim AS, El-Shishtawy MM, Pena A Jr. Liou GI. Genistein attenuates retinal inflammation associated with diabetes by targeting of microglial activation. Mol Vis 2010; 16: 2033-42.

  18. Antonetti DA, Klein R, Gardner TW. Diabetic Retinopathy. Mechanisms of disease. N Engl J Med 2012; 13: 1227-39.

  19. VanGuilder HD, Brucklacher AR, Patel K, et al. Diabetes downregulaes presynaptic protein and reduces basal synapin 1 phosphorylation in rat retina. Eur J Neuroci 2008; 28: 1-11.

  20. Gastinger MJ, Kunselman AR, Conboy EE, Bronson SK, Barber AJ. Dendrite remodeling and other abnormalities in the retinal ganglion cell of INS2 Akita diabetic mice. Invest Ophthalmol Vis Sci 2008; 49: 2635-42.

  21. Tang J, Kern TS. Inflammation in Diabetic Retinopathy. Prog Retin Eye Res 2011; 30: 343-58.

  22. Ryan S, Hinton D, Schachat A, Wilkinson C. Retina. 4th ed. St. Louis: Mosby-Yearbook; 2008.

  23. Simó R, Villarroel M, Corralia L, Hernández C, García-Ramírez M. The retinal pigment epithelium: something more than a constituent of the blood-retinal barrier-implications for the pathogenesis of diabetic retinopathy. Prog Rein Eye Res 2011; 30: 343-58.

  24. Goldin A, Beckman JA, Schidt AM, Creager MA. Advanced Glycation End Products. Sparking the Development of Diabetic Vascular Injury. Circulation 2006; 114: 597-605.

  25. Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care 2003; 26: 2653-64.

  26. Karkkainen MJ, Petrova TV. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymfhangiogenesis. Oncogene 2000; 19: 5598-605.

  27. Tamura H, Miyamoto K, Kiryu J, Miyahara S, Katsuta H, Hirose F, Musashi K, et al. Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthlmol Vis Sci 2005; 46: 1440-4.

  28. Chin MS, Nagineni CN, Hooper LC, Detrick B, Hooks JJ. Cyclooxygenase-2 gene expression and regulation in human retinal pigment epithelial cells. Investigative Ophthalmology and Visual Science 2001; 42(10): 2338-46.

  29. Ahuja M, Dhake AS, Sharma SK, Majumdar DK. Topical ocular delivery of NSAIDs. AAPS Journal 2008; 10(2): 229-41.

  30. Kim SJ, Flach AJ, Jampol LM. Nonsteroidal antiinflammatory drugs in ophthalmology. Survey of Ophthalmology 2010; 55: 108-33.

  31. Kim SJ, Toma HS, Barnett JM, Penn JS. Ketorolac inhibits choroidal neovascularization by suppression of retinal VEGF. Experimental Eye Research 2010; 91: 537-43.

  32. Kim SJ, Toma HS. Inhibition of choroidal neovascularization by intravitreal ketorolac. Archives of Ophthalmology 2010; 128: 596-600.

  33. Zweifel SA, Engelbert M, Khan S, Freund KB. Retrospective review of the efficacy of topical bromfenac (0.09%) as an adjunctive therapy for patients with neovascular age-related macular degeneration. Retina 2010; 29: 1527-31.

  34. Razo Blanco-Hernández DM, Lima-Gómez V, Asbun-Bojalil J. Eficacia del ketorolaco tópico para mejorar la función visual después de la fotocoagulación, en diabéticos con edema macular focal Cir Cir 2014; 82: 477-88.




2020     |     www.medigraphic.com